| 1 |
钱桂生. 肺癌不同病理类型发病率的变化情况及其原因[J/CD]. 中华肺部疾病杂志(电子版), 2011, 4(1): 1-5.
|
| 2 |
Hyuna S, Jacques F, Rebecca LS, et al. Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2021, 71(3): 209-249.
|
| 3 |
Oudkerk M, Liu S, Heuvelmans MA, et al. Lung cancer LDCT screening and mortality reduction-evidence, pitfalls and future perspectives[J]. Nat Rev Clin Oncol, 2021, 18(3): 135-151.
|
| 4 |
Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: Proposals for revision of the TNM stage groupings in the forthcoming (Eighth) edition of the TNM classification for lung cancer[J]. J Thorac Oncol, 2016, 11: 39-51.
|
| 5 |
Aberle DR, Adams AM, Berg CD, et al. National lung screening trial research team. Reduced lung cancer mortality with low-dose computed tomographic screening [J]. N Engl J Med, 2011, 365(5): 395-409.
|
| 6 |
范伟杰，张 冬. 影像组学及深度学习在肺结节良恶性鉴别诊断中的新理念[J/CD]. 中华肺部疾病杂志(电子版), 2021, 14(5): 549-553.
|
| 7 |
中华医学会呼吸病学分会肺癌学组，中国肺癌防治联盟专家组，肺结节诊治中国专家共识(2018年版)[J]. 中华结核和呼吸杂志，2018, 41(10): 763-771.
|
| 8 |
Horeweg N, van Rosmalen J, Heuvelmans MA, et al. Lung cancer probability in patients with CT-detected pulmonary nodules：a prespecified analysis of data from the NELSON trial of low-dose CT screening[J]. Lancet Oncol, 2014, 15(12): 1332-1341.
|
| 9 |
Jacobs C, van Ginneken B. Google′s lung cancer AI: a promising tool that needs further validation[J]. Nat Rev Clin Oncol, 2019, 16(9): 532-533.
|
| 10 |
Horeweg N, van der Aalst CM, Thunnissen E, et al. Characteristics of lung cancers detected by computer tomography screening in the randomized NELSON trial[J]. Am J Respir Crit Care Med, 2013, 187(8): 848-854.
|
| 11 |
Chang YY, Chen CK, Yeh YC, et al. Diagnostic feasibility and safety of CT-guided core biopsy for lung nodules less than or equal to 8 mm: A single-institution experience[J]. Eur Radiol, 2018, 28(2): 796-806.
|
| 12 |
朱 妍，王 剑. 肺小结节危险因素分析及恶性预测模型的建立[J/CD]. 中华肺部疾病杂志(电子版), 2020, 13(2): 223-228.
|
| 13 |
Roberts TJ, Lennes IT, Hawari S, et al. Integrated, multidisciplinary management of pulmonary nodules can streamline care and improve adherence to recommendations[J]. Oncologist, 2020, 25(5): 431-437.
|
| 14 |
Suresh S, Salama GR, Ramjit A, et al. CT-guided fine-needle aspiration biopsy of pulmonary nodules 8 mm or less has a higher diagnostic accuracy than positron emission tomography-CT[J]. J Vasc Interv Radiol, 2018, 29(4): 520-523.
|
| 15 |
叶 欣，范卫君，王忠敏，等. 热消融治疗肺部亚实性结节专家共识(2021年版)[J]. 中国肺癌杂志，2021, 24(5): 305-321.
|
| 16 |
Suh YJ, Park CM, Han K, et al. Utility of FDG PET/CT for preoperative staging of non-small cell lung cancers manifesting as subsolid nodules with a solid portion of 3 cm or smaller[J]. AJR Am J Roentgenol, 2020, 214(3): 514-523.
|
| 17 |
柯明耀，陈智德，曾俊莉，等. 肺磨玻璃结节诊治策略与消融治疗[J]. 中国胸心血管外科临床杂志，2022, 29(1): 11-22.
|
| 18 |
Heuvelmans MA, Walter JE, Peters RB, et al. Relationship between nodule count and lung cancer probability in baseline CT lung cancer screening: The NELSON study[J]. Lung Cancer, 2017, 113: 45-50.
|
| 19 |
Thakur MK, Ruterbusch JJ, Schwartz AG, et al. Risk of second lung cancer in patients with previously treated lung cancer: Analysis of surveillance, epidemiology, and end results (SEER) data [J]. J Thorac Oncol, 2018, 13(1): 46-53.
|
| 20 |
Liu C, Xiang X, Han S, et al. Blood-based liquid biopsy: Insights into early detection and clinical management of lung cancer[J]. Cancer Lett, 2022, 524: 91-102.
|
| 21 |
Abbosh C, Birkbak NJ, Swanton C. Early stage NSCLC-challenges to implementing ctDNA-based screening and MRD detection[J]. Nat Rev Clin Oncol, 2018, 15(9): 577-586.
|
| 22 |
Chen K, Bai J, Reuben A, et al. Multiomics analysis reveals distinct immunogenomic features of lung cancer with ground-glass opacity[J]. Am J Respir Crit Care Med, 2021, 204(10): 1180-1192.
|